Aktis Q3 Loss Widens to $29.9M; $492.9M Cash Funds Plan Into 2029
AKTS sits 22% above its 52-week low of $13.96.
Summary
Aktis reported a wider Q3 loss of $29.9M on higher trial spending, yet $492.9M in cash funds operations into 2029. The company also started a third Phase 1b trial and began in-house manufacturing, with first AKY-1189 data expected in Q1 2027.
Key Events · Earnings and Guidance · AKTS
-
Q3 Loss Widens on Trial Spending
Net loss was $29.9M versus $15.5M a year earlier, as R&D rose to $32.1M from $16.5M on advancing AKY-1189 and AKY-2519 trials.
-
Cash Runway Into 2029
Cash, cash equivalents and marketable securities totaled $492.9M at September 30, 2026, up from $226.8M at year-end 2025 after the January IPO, funding the operating plan into 2029.
-
Third Phase 1b Trial Started
BActinium-2 evaluating AKY-2519 in NSCLC and other B7-H3 expressing tumors began, alongside first backfill cohorts in NECTINIUM-2 and BActinium-1.
-
In-House GMP Manufacturing Begins
Aktis began manufacturing drug product at its 17 Drydock facility and expects to supply clinical trials from it in the first half of 2027.
Analysis · AKTS · Life Sciences
The balance sheet is the real story here: $492.9M in cash and securities funds operations into 2029, so there is no near-term financing need. The quarter's loss widened to $29.9M from $15.5M a year ago as R&D spending nearly doubled to $32.1M on three active Phase 1b trials. Clinical cadence also advanced — a third Phase 1b trial (BActinium-2 in lung cancer) started, backfill cohorts opened in the other two, and in-house GMP manufacturing began, with preliminary AKY-1189 data expected in Q1 2027. For a clinical-stage company, that combination of runway and pipeline execution is what drives the thesis.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AKTS was trading at $17.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $947.8M. The 52-week trading range was $13.96 to $34.19. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.